Does UnitedHealthcare Cover Ozempic in 2026? UHC Coverage Guide

For as much as UnitedHealthcare is known for—plans that go everywhere for weight loss drugs, here's a plan they've gone all out for, and it's an answer to the “Ozempic” phenomenon, and their answer is refreshingly uniform, with diabetes coverage not depending on optional employer riders.

Yes, UnitedHealthcare will pay for Ozempic in 2026 for type 2 diabetes in essentially all UnitedHealthcare commercial, Medicare Advantage and Community Plan (Medicaid) products. In most plans, doctors will probably need to add a GLP-1 (recent) and an A1C (diabetes test) as well as a “metformin trial” (a medication used to treat diabetes) to the plan before it will cover any of these plans. Weight loss coverage is available on plans that have dedicated weight management coverage, and do not cover weight loss (Ozempic) coverage, since this is not FDA approved.

The approval process with Optum Rx, the step therapy patterns, cost by plan type, and what to do, if denied. 

How Optum Rx Handles Ozempic

Ozempic has been added to the UnitedHealthcare's pharmacy benefit manager (PBM) Optum Rx standard formularies in the antidiabetic category, usually as a preferred brand, they report. Prior authorisation criteria are set at a national level, with the type 2 diabetes diagnosis (ICD 10) as a first criteria, followed by a recent A1C within 6 months, and step therapy to metformin unless contraindicated or not tolerated.

There are 2 Optum Rx specifics that members have. The PBM's move to discontinue annual reauthorization for patients on stable GLP-1 drugs will remove the paperwork jams that can occur during treatment. A new expanded indication (cardiovascular risk reduction in diabetics, and the new indication for kidney disease in January 2025) will give prescribers more approved reasons to document medical necessity when deciding to use the medicine.

Keep in mind the step-therapy approach described in your plan: some UHC plans are moving towards using Mounjaro or Trulicity first for GLP-1s. The most common denial is being unable to prove why the preferred agent or an agent in particular should be used in this case, so you need to start that argument on the preferred agent, or explain why. 

What Ozempic Costs on UnitedHealthcare in 2026

On the commercial side, preferred-brand copays range from $25 to $75 per month, and some copays are eligible (at $25 with Novonordisk's commercial savings card). For those enrolled in the high deductible (HSA) plan, they would pay the negotiated rate by UHC, which is about $550-$800, up to the deductible amount.

The 2026 federal protections are in place for UHC Medicare Advantage members, the nation's largest MA book, which includes the $245 negotiated government price from the November 2025 deal that Axios reported, a $50 monthly copay cap and the $2,100 annual Part D out-of-pocket maximum. The copay for UHC Community Plan members is ranging between $0 to $8 per state Medicaid. 

The Weight-Loss Boundary and the Right Doors

According to Optum Rx, diagnosis verification systems reliably reject Ozempic prescription for weight loss when it gets filled on GLP-1. Unlike Caremark, UHC included Wegovy on their plan coverage for the weight-management benefit (BMI 30+ or 27+ if covered for a medical condition), and Zepbound was also listed on Optum Rx formularies. People with diabetes can certainly be in the weight-loss program, as they are already having issues with diabetes.It's fair for a diabetes sufferer to be a part of the weight loss program, as they already have a problem with diabetes.

UHC Medicare Advantage members looking for weight management will be able to use the GLP-1 Bridge pilot, which will cover $50 copay caps for Wegovy and the Zepbound KwikPen, while maintaining the diabetes-only coverage.

Denials and the Fix Sequence

When a claim is denied as using UHC for the diagnosis of OZ, it is nearly always one of the following four gaps that the claimants are missing: UHC not in evidence, lack of evidence of metformin use, wrong GLP-1 first under step therapy, or expired authorization. Each fixes mechanically: resubmit with the lab, record the trial or contraindication, begin the preferred agent or explain about semaglutide, renew the authorization.

If the fixed resubmission is still unsuccessful, the formal ladder comes into play: internal appeal which is resolved within 30 days (72 hours under federal law when health is at risk); independent external review guaranteed under federal law. The A1C trends and cardiovascular and/or kidney indications are the most important prescriber letters.